MigraineMind research summary

Safety and Effectiveness of Pain Medications for Migraine Management During Pregnancy and Lactation.

Paediatr Drugs | 2026

Review
AuthorsSmirnoff L, Mancera NG, Hyppolite T, Lozano D, Cocores A
JournalPaediatr Drugs
Publication year2026
PubMed ID42440212

Summary

Managing migraines during pregnancy and lactation is quite challenging. There is limited safety data for migraine therapies during these periods. New treatments like CGRP blockers have little safety information. Established treatments such as topiramate and valproate carry known teratogenic risks. The safety evidence for propranolol and verapamil is also low quality. Efficacy data for verapamil is limited as well. Women experience migraines most frequently during their reproductive years. This requires a balanced approach to treatment. Both maternal and fetal risks must be considered. It is essential to provide effective treatments that benefit the patient. Recent studies suggest some newer medications may be safer. These include onabotulinumtoxinA, lidocaine nerve blocks, and triptans. This review aims to summarize the safety of various migraine medications. It focuses on those that are effective during pregnancy and lactation periods. Clinical relevance: This research emphasizes the need for safer migraine treatments during pregnancy and lactation.

Key Learning Points

  • Managing migraines during pregnancy and lactation is difficult due to limited safety data on available treatments.
  • Established migraine medications like topiramate and valproate have known risks for fetal development.
  • Newer treatments such as CGRP blockers lack sufficient safety information for use during pregnancy and lactation.
  • Women often experience migraines during reproductive years, necessitating careful consideration of treatment options.
  • Recent studies indicate that some newer therapies, like onabotulinumtoxinA and triptans, may offer safer alternatives for managing migraines.

Original research

Read the original publication and review its full methods and findings on PubMed.

MigraineMind is an educational resource designed to complement—not replace—the original scientific literature or clinical judgement. This page is an AI-generated summary of the available paper information and may contain errors. Please consult the original publication.